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ABSTRACT 
    Type 2 diabetes is a complex disease that is typically diagnosed in midlife and is characterized by progressive 
defects in insulin secretion and action.  Objective: to compare the effects of dipeptidyl peptidase-4 (DDP-4) 
inhibitor sitagliptin and sitagliptin in combination with omega-3 on blood glucose level, serum insulin, high 
sensitivity C-reactive protein a n d  oxidative stress state in newly diagnosed type 2 diabetic patients. Method: 
this is an open-label, randomized study carried out on 24 newly diagnosed type 2 diabetic patients. Patients 
were randomly divided into two groups and assigned for treatment with either sitagliptin (n=12) or sitagliptin in 
combination with omega-3 (n=12) for 2 months. The level of fasting blood glucose (FBG), post-prandial blood 
glucose (PPG), glycated hemoglobin (HbA1c), serum insulin, serum high sensitivity C-reactive protein (hs-CRP) 
and serum malondialdehyde (MDA) were calculated before and after one month and two months of treatment. 
Results: FBG, post prandial blood glucose and HbA1c significantly decreased in both treated groups after one 
month and two months of treatment. Serum insulin level increased non-significantly with sitagliptin and 
sitagliptin in combination with omega-3 after one and two months of treatment. Serum level of hs-CRP 
decreased significantly after two months of treatments with both sitagliptin and sitagliptin in combination with 
omega-3.  The level of serum MDA decreased significantly in group treated with sitagliptin in combination 
with omega-3 after one month and two months of treatment, while insignificant decrease observed after one 
a n d  t w o  months in sitagliptin treated group. Conclusion: omega-3 has no significant effect on glycemic 
control and insulin secretion but has beneficial effect on oxidative stress state, sitagliptin executes anti-
inflammatory effect in patients with type 2 diabetes. 
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INTRODUCTION 
        Diabetes is a problem with human body that causes blood glucose levels to rise higher than normal. Type 2 
diabetes is the most common form of diabetes.  Type 2 diabetes  characterized by that the body does not use 
insulin properly. This is called insulin resistance. At first, the pancreas makes extra insulin to make up for it. But, 
over time it isn't able to keep up and can't make enough insulin to keep blood glucose at normal levels. type 2 
diabetes seems to be associated with an increased risk of morbidity and mortality during the most productive 
years of life [1], such patients are at increased risk of developing macrovascular and microvascular 
complications. Whereas, patients with this form of diabetes may have insulin levels that appear normal or 
elevated, the higher blood glucose levels in these diabetic patients would be expected to result in even higher 
insulin values had their β-cell function been normal [2]. 
       Chronic low-grade inflammation is one of the hallmarks of obesity and type 2 diabetes. C-reactive protein 
(CRP) is a sensitive physiological marker of subclinical systemic inflammation, produced by the liver during 
acute infection or inflammation  and it is associated with hyperglycemia, insulin resistance, and overt type 2 
diabetes [3].   
       Type 2 diabetes mellitus is associated with multiple  metabolic derangements that result in the excessive 
production of reactive oxygen species and oxidative stress. Oxidative stress arises because of excessive 
production of reactive oxygen species (ROS) and impaired antioxidant defense mechanisms [4]. Multiple cellular 
studies have shown that under oxidative stress conditions, insulin signaling is impaired, resulting in insulin 
resistance of the cell [5].  
       Sitagliptin is a highly selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), which metabolizes 
the naturally occurring incretin hormones glucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic 
polypeptide (GIP) resulting in enhanced glucose-dependent insulin secretion from the pancreas and decreased 
hepatic glucose production. Since GLP-1 enhances insulin secretion in the presence of raised blood glucose 
levels, inhibiting DPP-4 activity will increase and prolong the action of GLP-1 by reducing its rate of inactivation 
in plasma [6].  
       Omega-3 polyunsaturated fatty acids (n-3 PUFA), include, alpha-linolenic acid (ALA, 18:3n-3) from plant 
sources, eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) from seafood [7].  
Omega-3 fatty acid from fish may play a role in glucose homeostasis, insulin action in peripheral tissues and 
pancreatic insulin secretion. Although the exact mechanisms are not well understood, the effects of omega-3 
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fatty acids on glucose metabolism could be partly mediated via alteration of both the phospholipid and protein 
components of cell membranes and regulation of peroxisome proliferator-activated receptor (PPAR) γ-dependent 
pathway [7]. 
In the present study, we sought to investigate the potential effects of omega-3 with sitagliptin on glycemic 
parameter, hs-CRP and lipid peroxidation in newly diagnosed type 2 diabetic Iraqi patients. 
 
MATERIALS AND METHODS 
Patient Selection 
      This study was carried out on twenty four patients (males and females) with type 2 diabetes mellitus; their 
ages range 40-55 years with newly diagnosed disease. They are randomly selected and assigned either to 
sitagliptin, or sitagliptin in combination with omega-3. They are maintained on dietary control program 
under the supervision of clinical nutrition specialist at National Diabetes Center for Treatment and 
Research/Al- Mustansiriyah University. All subjects were diagnosed with t y p e  2  d i a b e t e s  in 
accordance with the WHO diabetes diagnostic criteria of 1999 and had never been treated before. 
 
METHOD 
    After 12 hours overnight fasting, blood samples were analyzed for FBG, HbA1c, fasting insulin, hs-CRP, 
MDA, and then a solid meal was given and the blood glucose level was measured after 2 hours to calculate 
post-prandial blood glucose. All subjects were orally administered with either sitagliptin 100 mg given as a 
single daily dose in a tablet dosage form or sitagliptin 100 mg given once daily and 1000 mg omega-3 
given two times daily in a soft gel form. After one month and 2 months of the treatment, we measured the 
changes in  these parameters. FBG measured by using ready-made kit based on enzymatic colorimetric 
method, post prandial blood glucose measured by using blood glucose monitoring system (Accu-chek 
active roche). HbA1c determined by high- performance liquid chromatography (HPLC)(Bio-Rad Variant, 
U.S.A). Serum insulin was measured by using ready-made kit. The insulin kit is a solid phase enzyme-
linked immunosorbent  assay (ELISA) based on the sandwich principle. S e r u m  h s - C R P  
d e t e r m i n e d  b y  r e a d y m a d e  k i t .  The hs-CRP  (ELISA) is based on the principle of a solid phase 
enzyme-linked immunosorbent assay.  Serum MDA was measured by using ready-made kit (ELISA). This 
assay employs the competitive inhibition enzyme immunoassay technique. 
 
Statistical Analysis 
 
      Data are expressed as means ± SD. Statistics were performed using SPSS (version 19). Differences from 
baseline were assessed by the paired Student’s t test. A P-value of <0.05 was considered significant. 
 
RESULTS 
Patients 
      24 d i a b e t i c  patients randomly a l l o c a t e d  into two groups, first group includes: 12 p a t i e n t s  
t r e a t e d  w i t h  s i t a g l i p t i n  and second group includes: 12 patients treated with sitagliptin in 
combination with omega-3. All patients received the required doses of the study drug. There were no 
apparent differences between the two groups with respect to demographic and baseline characteristics (Table 
1). 
 
Efficacy 
      The changes from baseline to the end of the study are summarized in Table 2. FBG, PPG, HbA1c were 
significantly (p<0.05) decreased in both groups after one month and two months of treatment. Treatment with 
sitagliptin in combination with omega-3 showed no significant difference when compared with sitagliptin 
treated group (p>0.05) whether  after one month  or two months of treatment, with respect to the change in 
FBG, PPG, or HbA1c.Treatment with metformin alone or in 
combination with omega-3 produced slightly but no significant decrease in serum insulin level  (p>0.05), with no 
significant difference between these two groups after one month and two months of treatment (p>0.05). 
Treatment with metformin in combination with omega-3 produced significant decrease in serum MDA level 
compared to baseline values (p<0.05) after one month and two months of treatment, and significant reduction 
observed in metformin treated group after two months of  treatment (p<0.05), meanwhile insignificant decrease  
observed after one month of treatment with metformin (p>0.05). Treatment with metformin in combination with 
omega-3 showed significant difference when compared with metformin treated groups after one month and two 
months of treatment (p<0.05).  
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Table 1: Patient characteristic at baseline 
 
Table 2: Changes from baseline and after 1month and 2 months in glycemia, serum hs-CRP and MDA 
  
      
       Data are given as mean ± SD for baseline and end of study values for change from baseline; 
*significantly different compared to baseline level (P<0.05); values with non-identical superscripts  
(a,b) among different groups are considered significantly different (P<0.05). 
 
Sitagliptin+omega-3           Sitagliptin                    Variable/time point            
  FPG (mg/dl) 
219.25±14.89 221.75±10.47 Baseline 
189.25±10.07*a 192.08±8.79*a After 1 month 
13.68% 13.37% Change from baseline 
152.83±9.97*a 157.42±12.04*a After 2 months 
30.29% 29.01% Change from baseline 
  PPG (mg/dl) 
276.42±16.59 280.75±13.57 Baseline 
247.42±17.21*a 251.67±16.90*a After 1 month 
10.49% 10.35% Change from baseline 
209.67±12.93*a 217.83±17.38*a After 2 months 
24.14% 22.41% Change from baseline 
  HbA1c (%) 
9.82±1.18 9.75±1.69 Baseline 
8.55±1.12*a 8.68±1.14*a After 1 month 
12.93% 10.97% Change from baseline 
7.65±1.33*a 7.74±1.50*a After 2 months 
22.09% 20.61% Change from baseline 
  Insulin (µIU/ml) 
16.43±2.51 16.62±2.86 Baseline 
17.03±1.88a 17.32±1.21a After 1 month 
3.65% 4.21% Change from baseline 
17.45±1.37a 17.77± 1.81a After 2 months 
6.20% 6.91% Change from baseline 
  Hs-CRP(mg/L) 
4.58± 2.42 5.66± 2.90 Baseline 
3.75± 2.26a 4.91± 2.42a After 1 month 
18.12% 13.25% Change from baseline 
3.00± 1.20*a 4.45± 2.68*a After 2 months 
34.49% 21.37% Change from baseline 
  MDA(Mmol/L) 
4.16±1.04 5.15±1.37 Baseline 
3.45±0.96*b 4.92±1.60a After 1 month 
17.06% 4.46% Change from baseline 
2.70±1.62*b 4.64±1.79a After 2 months 
35.09% 9.90% Change from baseline 
Sitagliptin+omega-3 Sitagliptin                    Characteristic 
12 12 N=24 
40-55 40-55 Age; years 
219.25±14.89 221.75±10.47 FSG (mg/dl) 
276.42±16.59 280.75±13.57 PPG (mg/dl) 
9.82±1.18 9.75±1.69 HbA1c % 
16.43±2.51 16.62±2.86 Insulin (µIU/ml) 
4.58± 2.42 5.66± 2.90 Hs-CRP(mg/L) 
4.16±1.04 5.15±1.37 MDA (µmol/l) 
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Figure1. Effects of sitagliptin and sitagliptin in combination with omega-
3 on fasting blood glucose in type 2 diabetic patients. 
 
 
Figure 2. Effects of sitagliptin and sitagliptin in combination with omega-
3 on postprandial blood glucose level in type 2 diabetic patients. 
 
Figure 3. Effects of sitagliptin and sitagliptin in combination  with 
omega-3 on glycated hemoglobin in type 2 diabetic patients. 
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Figure 4. Effects of metformin and metformin in combination with 
omega-3 on serum insulin level in type 2 diabetic 
patients. 
 
 
 
Figure 5. Effects of sitagliptin and sitagliptin in combination with omega-3 
on serum insulin level in type 2 diabetic patients. 
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Figure 6. Effects of sitagliptin and sitagliptin in combination with omega-3 
on serum MDA level in type 2 diabetic patients. 
 
Discussion  
     Accelerated endogenous glucose production is thought to be a key factor in the development of fasting 
hyperglycemia in type 2 diabetes [8]. In the present study, the results regarding blood glucose and HbA1c 
indicated that there was a significant improvement in blood glucose levels and HbA1c after one month and two 
months of treatment with sitagliptin and sitagliptin plus omega-3, these results in agreement with previous 
studies [9,10]. Incretin hormones are rapidly degraded and removed from circulation by the enzyme DPP-4 
[11,12]. Therefore, there is considerable interest in enhancing incretin action for treatment of type 2 diabetes. 
Sitagliptin, a selective DPP-4 inhibitor, reduces both fasting and post-prandial plasma glucose presumably by 
inhibiting the inactivation of GLP-1 and GIP, thereby prolonging their duration of action on pancreatic islets 
[13,14]. The results of the present study showed that the combination of omega-3 with sitagliptin has no 
statistically  significant  effect  on glycemic control this is supported by reports of a non-significant change in 
fasting glucose after consumption of omega-3 fatty acids or fish oils [15]. Holman et al. found that 
administration of fish oil supplementation at relatively lower doses (1 to 2 g/day) for a period from 2-32 weeks 
may not have detrimental effect on glycemic status [16]. Shidfar et al. also reported that there was no effect on 
glycemic control or HbA1c with (2g/day) supplementation of omega-3 in patients with type 2 diabetes for 10 
weeks and attribute disparate findings to differences in diabetes medications, the presence of insulin resistance, 
hypertension, and obesity [17]. In contrast, the other reports found a significant increase in HbA1c and fasting 
glucose in type 2 diabetes patients after a fish diet [16] or omega-3 fatty acids [18]. 
In type 2 diabetes, defects in insulin secretion, tissue insensitivity to insulin and abnormalities in adipose tissue 
metabolism have been well documented [19]. Moreover, the difference in severity or secondary consequences of 
type 2 diabetes might result in different degrees of insulin concentration and resistance. 
      In the present study, the results showed that treatment with sitagliptin led to a non- significant increase 
compared with baseline values in fasting serum insulin level in agreement with previous studies [20,21], this 
consistent with its mechanism of action that is highly selective DPP-4 inhibitors enhance levels of active incretin 
hormones, gut-derived peptides that are released into the circulation after ingestion of a meal [22]. GLP-1 and 
GIP account for the majority of incretin action (23). In the presence of elevated glucose concentrations, GLP-1 
and GIP increase insulin release and GLP-1 lowers glucagon secretion, thereby decreasing the post-meal rise in 
glucose concentration and reducing fasting glucose concentrations [23]. The results of the present study showed 
that there was no difference in fasting serum insulin level between metformin and metformin plus omega-3 and 
between sitagliptin and sitagliptin plus omega- 3 treated groups. This agrees with other studies that approved 
omega-3 supplementation has no effect on fasting serum insulin level in type 2 diabetes patients [24]. Kristian et 
al. found glucose utilization was not affected by omega-3 fatty acids; neither was insulin secretion in patients 
with type 2 diabetes [25].  
  
       Treatment with sitagliptin produced significant reduction in hs-CRP level after two months; the results of 
the sitagliptin treatment were in agreement with previous studies [26,27]. Derosa et al. found that both 
metformin and sitagliptin treatment produced significant decrease in serum level of hs-C reactive protein with no 
difference between both agents [28]. Activation of the sympathetic system has numerous implications, including 
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surges of heart rate, blood pressure but also pro-inflammatory  and pro-coagulant effects, the anti-inflammatory 
effect of DPP-4 inhibitor may be partially explained by lack of repetitive sympathetic activations[29]. The 
results of the present study showed that sitagliptin plus omega-3 produced non-significant changes after one 
month of treatment, but decrease significantly after two months, with non-significant differences between 
sitagliptin and sitagliptin plus omega-3 treated groups, this mean that the addition of omega-3 supplementation 
produced non-significant reduction in hs-CRP level and the final effect may be due to combination effect of 
these two drugs. Our results in agreement with other several intervention studies that showed no significant 
effect of omega-3 supplementation on CRP for populations with type 2 diabetes [30,31]. C-reactive protein 
levels were not affected by omega-3 supplementation (3 g/day for eight weeks) in a randomized control trial for 
persons with type 2 diabetes [31]. Other study found no significant changes in CRP after two months 
supplementation with omega-3 for individuals with type 2 diabetes [30]. The mechanisms by which omega-3 
fatty acids decreased CRP may be through the inactivation of TLR4, this receptor generates downstream 
signaling cascades that lead to NF-κB activation and expression of COX-2, inflammatory cytokines and adhesion 
molecules. Another possibility is through the farnesoid  X receptor (FXR), omega-3 fatty acids are ligands for 
FXR. Farnesoid  X receptor is a member of the nuclear hormone receptor super family that functions as a ligand-
activated transcription factor. When activated, FXR can down-regulate the expression of IL-1 and IL-6 which are 
regulated the synthesis of CRP [32].  
Oxidative stress is proposed to be an early event in the pathology of DM and may influence the onset and 
progression of late complications [33]. The present study showed non-significant reduction in serum MDA level 
after one month and two months of sitagliptin treatment consistent with previous studies [34]. Liliana Ferreira et 
al. observed that there was no significant difference in serum MDA level after sitagliptin treatment for 6weeks. 
On the contrary, they observed a significant reduction of pancreas and heart MDA in the sitagliptin-treated 
Zucker diabetic fatty rats [35].The possible explanation is through the activities of the superoxidase dismutase, 
glutathione peroxidase, glutathione S transferase were increased in sitagliptin treatment [36]. Our results showed 
that treatment with sitagliptin plus omega-3 resulted in significant reduction in serum level of MDA after one 
month and two months of treatment , with significant difference between sitagliptin and sitagliptin plus omega-3 
treated groups. This confirms thatomega-3 fatty acid supplementation led to a significantly lower the level of 
MDA when compared with the baseline values, these results consistent with previous studies [17]. Other studies 
showed no effect of omega-3 on serum level of MDA after two months in type 2 diabetic patients [30], Brita et 
al. observed that there were no significant changes in serum MDA level after fishy diet rich in omega-3 fatty 
acids for 3.5 weeks in patient with type 2 diabetes [37]. 
Potential mechanisms for the decrease in MDA may be related to the assembly of omega-3 fatty acids in 
membrane lipids and lipoproteins making the double bonds less available for free radical attack, inhibition of the 
pro-oxidantenzyme phospholipase A2 and stimulation of anti-oxidant enzymes [38,39]. In this regard, omega-3 
fatty acids upregulate gene expression of antioxidant enzymes and down regulate genes associated with 
production of reactive oxygen species [40]. 
 
CONCLUSION 
• Omega-3 has no significant effect on glycemic control and insulin secretion but has beneficial effect on 
oxidative stress state. 
• Sitagliptin executes anti-inflammatory effect in patients with type 2 diabetes. 
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